What's New At Isto.

The acquisition of TheraCell, Inc. will expand access for two best-in-class product portfolios and build upon Isto’s continued commitment to putting patients and their surgical champions first.

We’re proud to announce the next installment of our Regenerative Medicine Educational Series. Our semi-annual peer-to-peer events explore physician-focused topics regarding the advancements in biologics and autologous therapy in medicine.

Isto Biologics’ Medical Education team recently supported a biologics Hospital-Based Observation Preceptorship led by Dr. Edgardo Rodriguez, DPM.

Isto Holdings, the parent company of St. Louis-based Isto Biologics has acquired Progenicare, a national medical sales and service company.

Isto Biologics’ Medical Education team recently supported a cadaver lab led by Dr. Blake Johnson, Medical Director at CDI – Twin Cities MN.

Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis with $1.5 billion of assets under management, announced today that it has acquired the commercial operations of ISTO Technologies (ISTO) headquartered in St. Louis, MO.

ISTO Technologies, Inc., a privately-held orthobiologic regenerative medicine company, announces the publication of positive clinical results reported for InQu® Bone Graft Extender & Substitute in a comparative study of two bone graft materials in posterolateral lumbar fusion.